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Abstract
Introduction: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the
US. SAP is associated with reductions in quality of life and ability to work, and increased use of healthcare resources. Ivabradine is a
drug with a unique therapeutic target, the If current of the sinus node, developed for the treatment of cardiovascular diseases including
SAP. It has an exclusive heart rate reducing effect, without any negative effect on left ventricular function or coronary vasodilatation.
Aims: The aim of this paper is to review the evidence concerning the use of ivabradine in the treatment of SAP.
Evidence review: Ivabradine is an effective antianginal and antiischemic drug, not inferior to the beta blocker atenolol and the calcium
channel antagonist (CCA) amlodipine. It decreases the frequency of angina attacks and increases the time to anginal symptoms during
exercise. Because of its exclusive chronotropic effect, ivabradine is not associated with the typical adverse reactions associated with
beta blockers or other antianginal drugs.
Clinical value: Clinical evidence shows that ivabradine is a very good antiischemic and antianginal agent, being as effective as beta
blockade and CCA therapy in controlling myocardial ischemia and symptoms of stable angina. Ongoing studies will determine the
potential of ivabradine to improve morbidity and mortality in coronary artery disease and heart failure.
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Core evidence clinical impact summary for ivabradine in angina
Outcome measure Evidence Implications
Patient-oriented evidence
Decrease in angina attack frequency Clear Ivabradine reduces the frequency of angina attacks at least as effectively as atenolol and amlodipine
Decrease in short-acting
nitrate consumption
Clear Ivabradine reduces the need for short-acting nitrate consumption as well as atenolol and amlodipine
Increase in time to angina onset and
to limiting angina during exercise
Clear Ivabradine 7.5 mg bid is as effective as atenolol 100 mg od and amlodipine 10 mg od in increasing time
to angina onset and time to limiting angina during exercise
Increase in total exercise duration Clear Ivabradine 7.5 mg bid is as effective as beta blockade (atenolol 100 mg od) and calcium channel
antagonist (amlodipine 10 mg once daily) therapy in increasing total exercise duration
Absence of rebound effect
after withdrawal
Clear No rebound effect (unlike beta blockers) and no drug tolerance (unlike nitrates) with ivabradine
Reduction in mortality No evidence The BEAUTIFUL and SHIFT trials are ongoing
Disease-oriented evidence
Increase in time to 1 mm ST segment
depression during exercise
Clear Ivabradine 7.5 mg bid is equivalent to atenolol 100 mg od and amlodipine 10 mg od in increasing time
to 1 mm ST segment depression during exercise tolerance testing
Decrease in heart rate Clear Heart rate at rest and during exercise is significantly reduced with the use of ivabradine
Decrease in heart rate-pressure
product
Clear Ivabradine decreases the rate-pressure product
Economic evidence
Cost effectiveness in the treatment
of SAP
No evidence Studies required
bid, twice daily; od, once daily; SAP, stable angina pectoris.Scope, aims, and objectives
Stable angina pectoris (SAP) is an ischemic heart disease
affecting 30 000 to 40 000 per million people in Europe and the
US (ESC 2006). Besides the burden of a reduced quality of life,
patients with SAP have a higher risk of experiencing major
cardiovascular events such as myocardial infarction (MI) and
unstable angina. Thus, the management of SAP involves
secondary prevention as well as symptomatic treatment. It
includes therapeutic lifestyle changes, drug therapy, and, to a
lesser extent, invasive procedures. The medications currently
used for the management of SAP are mainly beta blockers (e.g.
atenolol), calcium channel antagonists (CCAs) (e.g. amlodipine),
and nitrates. Over the last decade, a new therapeutic target, the f
channel in the sinus node, has been evaluated and the If current
inhibitor ivabradine (Procoralanﾮ, Corlentorﾮ, Coralanﾮ,
Coraxanﾮ, Servier) was approved for the treatment of SAP by the
European Medicines Agency (EMEA) in 2005. This new
pharmacologic agent provides a unique mechanism of action
involving an exclusive reduction in heart rate (HR), without any
inotropic or coronary vasoconstrictive effect.
The aim of this review is to describe the clinical evidence for the
role of ivabradine in the treatment of SAP.
Methods
A search of medical literature was conducted for relevant
information about the role of ivabradine in the treatment of angina.
The terms “ivabradine” and “angina” were used for the search,
and it was limited to English language articles. The databases
used were:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez, 1996 to date
• EMBASE, http://www.datastarweb.com, 1974 to date
• BIOSIS, http://www.datastarweb.com
• York University Centre for Reviews and Dissemination
databases
• Cochrane Databases of Systematic Reviews (CDSR),
http://www.cochrane.org/index.htm (entire site searched).
Articles concerning animal and in-vitro studies were excluded. No
systematic reviews or meta analyses were identified in this
literature search. Among all the articles found, three articles and
one abstract were included in the final evidence base as level 2
clinical evidence records (Table 1).
Disease overview
SAP is an ischemic heart syndrome typically characterized by
brief chest discomfort, lasting usually less than 10 min,
triggered by exertion or emotional stress. As a common
manifestation of coronary artery disease (CAD), SAP is
therefore caused by an imbalance between the oxygen demand
of the heart and the blood flow to the myocardial cells. It is
usually described as a constrictive or burning sensation located
near the sternum, but it can radiate to the epigastrium, the
neck, the jaw, and the arms, especially the left one. The
symptoms of pain associated with SAP can be relieved by rest
or by short-acting sublingual nitroglycerin. Dyspnea and
palpitations can come along with the pain, or can occur as
equivalent SAP symptoms. Chest pain can be classified
according to the following characteristics involved in the
syndrome: (1) substernal chest discomfort of characteristic
quality and duration; (2) provoked by exertion or emotional
stress; and (3) relieved by rest and/or nitroglycerin. Typical
angina involves all three characteristics and atypical angina
involves two of them, while noncardiac chest pain usually
involves one or none of them (Diamond 1983). More than half of
patients experience anginal symptoms at least once a week
(Gandhi et al. 1995).
Multiple diseases have the potential to predispose to angina
episodes, including aortic stenosis, left ventricular hypertrophy,
hypotension, arrhythmias, and anemia, but the most commonly
encountered etiology is coronary stenosis due to
atherosclerosis in CAD. Quality of life is reduced with SAP, with
the majority of patients perceiving that they have a poor or fair
health condition, and this proportion increases with the
frequency of the angina episodes (Pepine et al. 1998). This
condition affects significantly more women than men overall,
but the prevalence is higher in men aged under 70 (Deckers
2005). It is believed that estrogens may play a protective role
against atherosclerosis and SAP, and postmenopausal women
are affected by CAD two- to three-fold more than
premenopausal women (Kannel et al. 1976). In a cohort of
patients with SAP observed in the early 1990s, female patients
were significantly older than men, and the prevalence of
cardiovascular conditions associated with SAP was 70%
(Pepine et al. 1998). The prevalence of SAP increases with age,
varying from 2–5% to 11–20% in men aged 45–54 years and
65–74 years, respectively (Tendera 2005). In women, the
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Category Number of records
Full papers Abstracts
Initial search 116 1
records excluded 108 0
records included 81
Additional studies identified 00
Level 1 clinical evidence 00
Level 2 clinical evidence (RCT) 31
Level ≥3 clinical evidence 00
trials other than RCT 00
case studies 00
Economic evidence 00
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review3
prevalence is 0.5–1.0% and 10–14% for the same age groups.
In the US, the incidence of SAP is 400 000 per year, and
452 300 people died because of CAD in 2004, with a higher
proportion for males. In the UK, a study has shown that the
annual incidence of SAP is 2.03 for men and 1.89 for women
per 100 people (AHA 2008).
The grading of SAP used to evaluate its severity comprises four
angina classes, according to the Canadian Cardiovascular
Society Classification (Table 2). This classification is useful to
assess patients’ quality of life and to determine their response
to therapy. In a study conducted in the mid-1990s,
approximately 11% of the patients diagnosed with de novo
SAP experienced nonfatal MI or death within one year of follow-
up (Gandhi et al. 1995). The probability of experiencing an
acute coronary syndrome when suffering from SAP increases
with the presence of CAD risk factors. The typical CAD risk
factors are smoking, hypertension, dyslipidemia, physical
inactivity, obesity, and diabetes mellitus (AHA 2008).
A high HR is an important risk factor for experiencing an episode
of angina, given that it shortens the perfusion time of the
myocardium by decreasing the duration of diastole, and also
because it increases the oxygen demand of the heart. HR is one
of the most important determinants of myocardial oxygen
demand. Furthermore, an elevated HR at rest is associated with
increases in all-cause mortality, cardiovascular mortality, and
time to cardiovascular rehospitalization in patients with CAD,
independently of major cardiovascular risk factors (Kannel et al.
1987; Mensink et al. 1997; Diaz et al. 2005). It is also
independently associated with greater coronary atherosclerosis
progression (Perski et al. 1992). The in-hospital HR of patients
hospitalized for acute MI is an independent risk predictor of
mortality at one year (Fox et al. 1996). Moreover, a HR over
80 beats per min (bpm) is associated with an increased risk of
atherosclerotic plaque rupture (Heidland et al. 2001). In patients
suffering from the metabolic syndrome or hypertension, the HR
at rest is also associated with increased mortality (Diaz et al.
2005). A recent meta regression analysis has shown that
reducing HR may be associated with a decrease in
cardiovascular morbidity and mortality (Cucherat 2007).
Current therapeutic options in stable
angina pectoris
The aims of the treatment of SAP are both to prevent MI and
cardiac death and to decrease the frequency and severity of the
symptoms in order to improve functional capacity (Gibbons et al.
2002; ESC 2006). Therefore, the goal is to increase both the
quantity and the quality of life, with a greater focus on secondary
prevention to improve prognosis. The general management of
patients with SAP includes therapeutic lifestyle changes targeting
risk factors that may have been involved in the development of the
disease, pharmacologic intervention, and, if necessary,
revascularization. Risk factor management includes smoking
cessation, weight control, physical activity, and the medical and
lifestyle control of hypercholesterolemia, diabetes mellitus, and
hypertension. Drugs recommended for the prevention of major
cardiovascular events in CAD patients include antiplatelet agents
(particularly aspirin), lipid-lowering agents (particularly statins), and
angiotensin-converting enzyme (ACE) inhibitors (Gibbons et al.
2002; ESC 2006). The most effective agents currently available to
control anginal and ischemic symptoms are beta blockers, CCAs,
and nitrates. These drugs all have the ability, through different
mechanisms and to different extents, to decrease the heart’s
oxygen demand and to increase the perfusion to the myocardium.
Beta blockers are recommended as the initial symptomatic
therapy of SAP if there is no contraindication, with a higher level
of evidence for patients with prior MI (Gibbons et al. 2002; ESC
2006). A strong positive correlation exists between the reduction
in HR with beta blockers and the decrease in mortality among
post-MI patients (Singh 2001). Beta blockers decrease the heart’s
oxygen demand primarily by slowing HR, in addition to reducing
blood pressure and myocardial contractility (Guth et al. 1987;
Egstrup 1988; Saha & Marber 2005). These agents are also
capable of increasing exercise tolerance and decreasing nitrate
consumption. The dose of beta blocker is usually adjusted to a
target HR of 50–60 bpm in patients with SAP if there is no
contraindication or side effect. No systematic review has been
conducted to assess changes in quality of life of patients with
SAP treated with beta blockers. Of note, beta blockers must be
avoided in patients with vasospastic angina.
The use of CCAs to reduce the symptoms of SAP is
recommended if beta blockers are contraindicated. This class of
agent can also be prescribed in combination with long-acting
nitrates or beta blockers; dihydropyridine CCAs are preferable
when used in conjunction with beta blockade (Wallace et al. 1994;
Fox et al. 1996; Rehnqvist et al. 1996; Heidenreich et al. 1999;
AHA/ACA 2002; ESC 2006). CCAs exert their action by their
negative inotropic effect, and their ability to produce peripheral
vasodilatation (thus reducing blood pressure) and to decrease
coronary vascular resistance. Thus, the antianginal and
antiischemic properties of CCAs are mediated by their ability to
decrease the heart’s oxygen demand and increase coronary flow
(Brogden et al. 1996). Long-acting CCAs have generally been as
effective as beta blockers in relieving angina symptoms, and
improving time to ischemia and time to onset of angina during
exercise (Gibbons et al. 2002).
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Class Level of symptoms
l “Ordinary activity does not cause angina”
Angina with strenuous or rapid or prolonged exertion only
ll “Slight limitation of ordinary activity”
Angina on walking or climbing stairs rapidly, walking uphill, or
exertion after meals, in cold weather, when under emotional
stress, or only during the first few hours after awakening
lll “Marked limitation of ordinary physical activity”
Angina on walking one or two blocks on the level or one flight of
stairs at a normal pace under normal conditions
lV “Inability to carry out any physical activity without discomfort” or
“angina at rest”
Table 2 | Classification of angina severity according to the
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The antianginal properties of nitrates can be attributed to the
augmentation of coronary flow and to the decrease in the heart’s
oxygen consumption that they cause. Nitrates induce coronary
vasodilatation, leading to better myocardial perfusion. They also
produce venodilatation, leading to decreased venous return, and
thus to reduced cardiac preload. Nitroglycerin also exerts
antiplatelet effects in patients with SAP (Lacoste et al. 1994).
Short-acting nitroglycerin is used sublingually to relieve symptoms
of angina. Long-acting nitrates can be used in combination with a
beta blocker if monotherapy has proven unsuccessful, or in
combination with CCAs if beta blockade leads to unacceptable
adverse drug reactions. During exercise, nitrates increase the
delay before the onset of angina and the time to
1 mm ST segment depression (TST), but their effects are improved
when used in combination with another antianginal agent (Akhras
et al. 1991). Nitrates should be administered intermittently, with
8 to 12 hours of nitrate-free intervals, to prevent pharmacologic
tolerance. However, a rebound phenomenon with anginal
symptoms is possible during these intervals.
Other antianginal agents include potassium channel activators,
trimetazidine, L-carnitine, ranolazine, and ACE inhibitors, but their
clinical efficacy remains to be proven. With the exception of ACE
inhibitors in patients with concomitant CAD and diabetes or left
ventricular systolic dysfunction (Gibbons et al. 2002; ESC 2006),
no guidelines currently recommend the use of these agents in the
treatment of SAP.
In summary, for the prevention of anginal symptoms, current
guidelines (Gibbons et al. 2002; ESC 2006) recommend beta
blockers as the first-line therapy, particularly in post-MI patients,
and combination with CCAs or long-acting nitrates can be used if
the initial treatment is unsuccessful. If intolerance to beta blockers
develops, or in the presence of contraindications, monotherapy
with a CCA, an If inhibitor (where available), a long-acting nitrate,
or a potassium channel opener is indicated. These agents can be
used in combination if monotherapy is not effective. Surgical or
percutaneous revascularization should be reserved for patients
whose symptoms are not well controlled by optimal medical
therapy, or for those with severe left main coronary artery disease
or severe multivessel disease.
Unmet needs
The main limitations of current pharmacologic therapy for SAP are
the contraindications and side effects of the different classes of
antianginal agents. Patient compliance with beta blockers can be
limited by side effects such as fatigue, sexual dysfunction,
bronchospasm, cold extremities, worsening claudication, light
headedness, gastrointestinal disturbances, bradycardia, and
atrioventricular (AV) block (Tafreshi & Weinacher 1999; Gibbons et
al. 2002; Ko et al. 2002; ESC 2006). In addition, beta blockers can
be associated with unfavorable metabolic effects on glycemic
control and on the lipid profile, as well as with inhibition of the
adrenergic response to hypoglycemia. Contraindications for beta
blockers include severe bradycardia, high-degree AV block, sick
sinus syndrome, and unstable heart failure (Gibbons et al. 2002).
The presence of asthma or chronic obstructive pulmonary
disease represents a relative contraindication to beta blockade
(Gibbons et al. 2002). A rebound increase in myocardial ischemia,
potentially associated with tachycardia, hypertension, MI, and
unstable angina, after abrupt withdrawal of beta blocker therapy,
makes progressive dosage reduction necessary when withdrawal
of beta blockade is needed (Frishman 1987; Egstrup 1988). Many
patients are not prescribed beta blockers after MI, despite the
strong evidence of benefit when these agents are used for
secondary prevention in this setting (Hanania 2004). Despite the
availability of beta blockers, resting HR may not be sufficiently
controlled to the target of 55–60 bpm. In one recent study,
patients with CAD had a mean HR of 70 bpm despite use of beta
blockers by 61% of patients (Newby et al. 2006).
Side effects of CCAs include hypotension, lower extremity edema
(with dihydropyridine CCAs), and constipation (with verapamil).
The contraindications for the use of nondihydropyridine CCAs are
bradycardia, AV conduction block, and sinus node dysfunction.
CCAs should also not be used in patients with both SAP and left
ventricular systolic dysfunction, except for amlodipine, which has
been shown to be safe in this setting. Some reports have
indicated that immediate-release and short-acting CCAs could
increase the risk of cardiovascular mortality in patients with SAP,
diabetes and/or hypertension in a dose-related fashion, and these
formulations should therefore not be used (Furberg et al. 1995;
Estacio et al. 1998).
The most frequent side effect of nitrates is headache, reported by
up to 82% of patients in placebo-controlled trials in a dose-related
fashion, with about 10% of patients reporting severe symptoms
leading to discontinuation of the treatment (Thadani & Rodgers
2006). Hypotension is frequent and usually asymptomatic,
although syncope can rarely occur. The tolerance phenomenon
associated with the chronic use of long-acting nitrates imposes
the need for an 8–12 hour nitrate-free interval every day, which can
occasionally lead to angina attacks at night during this period.
Nitrates are contraindicated in patients with severe aortic stenosis
or hypertrophic obstructive cardiomyopathy. Furthermore,
concomitant use of nitrates and sildenafil can provoke severe
potentially life-threatening hypotension, making this combination
an absolute contraindication. Indeed, patients should be warned
never to use sildenafil within 24 hours of nitrate consumption
(Cheitlin et al. 1999).
Ivabradine is an inhibitor of the selective cardiac pacemaker
hyperpolarized-activated If current, one of the most important
pacemaker currents in the sinoatrial node (DiFrancesco & Camm
2004; Zaza & Rocchetti 2005). Ivabradine has no negative
inotropic or hypotensive effects and is therefore a pure HR-
lowering agent, in contrast to beta blockers. The results of
clinical trials with ivabradine are described below. According to
the European Society of Cardiology guidelines (ESC 2006),
ivabradine is recommended in patients with SAP who do not
tolerate beta blockers. The pure HR-reducing effect of ivabradine
offers the advantage of not disturbing hemodynamic parameters
or left ventricular systolic and diastolic functions (Manz et al.
2003). Unlike beta blockers, ivabradine does not decrease the
diameter of epicardial coronary arteries at rest and the5
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augmentation during exercise (Simon et al. 1995). Moreover, the
increase in the duration of diastole is greater with ivabradine than
with atenolol for a given HR (Colin et al. 2003), a beneficial
phenomenon considering that most of the coronary perfusion
occurs during diastole.
Clinical evidence with ivabradine
In this review, it is shown that there is clear evidence that
ivabradine is efficacious in reducing HR and decreasing angina
attack frequency and short-acting nitrate consumption. The
antiischemic and antianginal effects of ivabradine are comparable
to those of widely prescribed therapeutic agents from other
classes used in SAP.
A phase III clinical trial has been conducted to evaluate the clinical
impact of ivabradine in the treatment of SAP, and phase IV studies
are ongoing because the European approval for the marketing of
ivabradine is relatively recent (2005). The present review focuses
on three randomized controlled trials involving ivabradine
monotherapy for patients with SAP (Borer et al. 2003; Tardif et al.
2005; Ruzyllo et al. 2007), plus a subgroup analysis from one of
these studies (Tendera et al. 2006). No systematic review or meta
analysis is included in this review.
Antianginal effects
Time to angina during exercise (Table 3)
In the first randomized clinical trial (n=360 patients) testing the
antianginal effects of ivabradine (Borer et al. 2003), the time to
angina onset and to limiting angina during exercise tolerance test
at trough of drug activity (12 hours after drug administration)
increased significantly in patients who received ivabradine 10 mg
twice daily for two weeks (n=66) compared with placebo (n=68).
The mean time to angina onset increased by 69.4ﾱ74.8 s in the
ivabradine group, while it increased by 24.7ﾱ64.2 s in the
placebo group (P<0.05). Mean time to limiting angina, which was
the primary efficacy endpoint of the study, increased by
40.8ﾱ69.3 s and 12.7ﾱ51.3 s, respectively (P<0.05). A similar
trend was observed in patients receiving ivabradine 5 mg twice
daily (n=59), but it did not reach significance. At peak plasma
concentration (4 hours after drug administration), the effects
were greater, also reaching significance in the group receiving
ivabradine 5 mg twice daily.
After the double-blind phase of the trial, patients entered an
open-label phase during which they received ivabradine 10 mg
twice daily for 2 or 3 months, followed by a double-blind
withdrawal period in which patients were randomized to placebo
or to ivabradine 10 mg twice daily. During the open-label phase,
time to limiting angina was maintained in patients assigned to
ivabradine in the first part of the trial, and it increased in patients
who had initially received placebo during the first phase. During
the withdrawal phase, time to limiting angina and time to angina
onset were significantly longer (P=0.018 and P=0.002,
respectively) in patients who were assigned to remain on
ivabradine compared with those receiving placebo.
In 2005, the INITIATIVE investigators published the results of a
randomized controlled trial involving 939 patients with SAP (Tardif
et al. 2005) in which the noninferiority of ivabradine relative to the
beta blocker atenolol was assessed. Study patients were
randomized into three groups and therapy was administered
for a period of 16 weeks: (1) ivabradine 5 mg twice daily for
4 weeks followed by ivabradine 7.5 mg twice daily for 12 weeks;
(2) ivabradine 5 mg twice daily for 4 weeks followed by ivabradine
10 mg twice daily for 12 weeks; or (3) atenolol 50 mg once daily
for 4 weeks followed by atenolol 100 mg once daily for 12 weeks.
At 16 weeks, patients who were assigned ivabradine 7.5 mg twice
daily and 10 mg twice daily had a mean increase of time to limiting
angina of 91.8ﾱ131.1 s and 96.9ﾱ121.1 s, respectively, at trough
drug concentrations, versus 85.4ﾱ133.7 s for atenolol 100 mg
once daily (P<0.001 for noninferiority of ivabradine). The efficacy
of ivabradine relative to atenolol was also established for time to
angina onset (P<0.001 for noninferiority). During the first 4 weeks
of the trial, when the doses were lower, the noninferiority of
ivabradine was also established at trough and at peak of drug
activity for time to limiting angina and time to angina onset
(P<0.001 for noninferiority).
The efficacy of ivabradine 7.5 mg twice daily and 10 mg twice daily
versus the long-acting CCA amlodipine 10 mg once daily for time
to angina onset was also established (P<0.001 for noninferiority) at
trough of drug activity in patients with SAP in a 3-month
randomized, double-blind trial (Ruzyllo et al. 2007). The increases
in time to angina onset were 64.7ﾱ104.9, 59.7ﾱ110.8, and
66.6ﾱ99.1 s (P<0.05), respectively, and the maximal improvement
was reached by the end of the first month of therapy.
Total exercise duration (Table 3)
The noninferiority of ivabradine for total exercise duration during
exercise tolerance testing was established relative to atenolol
(Tardif et al. 2005) and amlodipine (Ruzyllo et al. 2007) as the
primary efficacy endpoint of these trials. In the latter trial, over a
3-month period, ivabradine 7.5 mg twice daily and 10 mg twice
daily produced improvements of 27.6ﾱ91.7 s and 21.7ﾱ94.5 s,
respectively, in total exercise duration on a bicycle at trough of
drug activity, while amlodipine 10 mg once daily produced an
increase of 31.2ﾱ92.0 s. The noninferiority of ivabradine versus
amlodipine was significant for both dosages (P<0.001).
In the INITIATIVE noninferiority trial comparing ivabradine with
atenolol (Tardif et al. 2005), total exercise duration during treadmill
exercise tolerance tests performed according to a modified Bruce
protocol at trough drug activity increased by 86.8ﾱ129.0 s with
ivabradine 7.5 mg twice daily, 91.7ﾱ118.8 s with ivabradine 10 mg
twice daily, and 78.8ﾱ133.4 s with atenolol 100 mg once daily
after 16 weeks compared with baseline (P<0.001 for noninferiority
of ivabradine versus atenolol). Noninferiority of ivabradine was
also shown at peak drug activity after 4 weeks and 16 weeks
of treatment, and at trough drug activity after 4 weeks.
Interestingly, elderly patients randomized in the INITIATIVE trial
showed a tendency to greater effectiveness of ivabradine relative
to the overall study population, in contrast to atenolol (Tendera
et al. 2006).Ivabradine | clinical impact review
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Angina attack frequency (Table 4)
In a randomized, placebo-controlled trial (Borer et al. 2003), the
frequency of angina attacks was assessed at the end of an open-
label phase during which 161 patients with chronic SAP were
assigned to a regimen of ivabradine 10 mg twice daily for
3 months, following a 2-week period during which they received
one of the four following regimens in a double-blind fashion:
ivabradine 2.5 mg twice daily, ivabradine 5 mg twice daily,
ivabradine 10 mg twice daily, or placebo. At the end of this
3-month period, the number of angina attacks per week, as
recorded in patients’ diaries, was found to be significantly lower
than at baseline, decreasing from 4.14ﾱ5.58 attacks per week to
0.95ﾱ2.24 attacks per week (P<0.001) (Table 4). The consumption
of short-acting nitrates decreased from 2.28ﾱ3.74 U/week to
0.50ﾱ1.14 U/week (P<0.001) during the same period. In a
subsequent 1-week withdrawal period following the 3-month
open-label phase, angina attack frequency increased by
0.74ﾱ1.95 attacks per week for patients assigned to placebo
(P=0.067).
The number of angina attacks per week and short-acting nitrate
consumption decreased in all groups of patients in the
INITIATIVE trial after 4 and 16 weeks, with no significant
difference observed between the ivabradine and atenolol
groups (Tardif et al. 2005) (Table 4). Angina attacks were
reduced by at least 70% and short-acting nitrate consumption
by approximately 66% in all study groups at 16 weeks. It has
also been shown that there are no significant differences in the
reduction of the number of angina attacks and short-acting
nitrate consumption between ivabradine 7.5 mg twice daily and
10 mg twice daily versus amlodipine 10 mg once daily (Ruzyllo
et al. 2007). These two parameters decreased significantly by




Reference Design and patients Treatment regimen Outcomes
Time to angina during exercise Total exercise duration








IVA 2.5–10 mg bid vs
PLA for 2 wk; then open-
label phase with IVA
10 mg bid for all patients
for 3 months; then IVA 10
mg bid vs PLA for
1 wk
TAO and TLA increased at all doses in the
first phase of the trial, but reached
significance only for IVA 10 mg bid at
trough of drug activity, and for IVA 5 and
10 mg bid at peak of drug activity
In the open-label extension, the increase
in TLA with IVA was significant vs PLA
(P<0.001)
During the third phase of the trial, TLA
and TAO were significantly higher with
IVA than with PLA (P=0.018 and P=0.002,
respectively)
Not evaluated
2 Tardif et al.
2005
RCT (noninferiority trial),
939 patients with SAP
and CAD
IVA 5 mg bid vs ATE
50 mg od for 4 wk; then
IVA 7.5 mg bid or 10 mg
bid vs ATE 100 mg od for
12 wk
TAO increased by 145.2ﾱ153.4 s and
139.6ﾱ140.6 s for IVA 7.5 and 10 mg
bid, respectively vs 135.2ﾱ154.7 s for
ATE (P<0.001 for noninferiority) at
trough of drug activity after 16 wk
Noninferiority also shown after 4 wk
(P<0.001)
For the same time periods, TLA
increased by 91.8ﾱ131.1 s, 96.9ﾱ
121.1 s, and 85.4ﾱ133.7 s for the same
groups (P<0.001 for noninferiority)
At peak of drug activity, noninferiority
for TLA and TAO shown after 4 wk and
16 wk for IVA vs ATE
Noninferiority for TLA was also
established at 4 wk and at 16 wk at
both trough of drug activity and peak of
drug activity for IVA vs ATE
Increase of 86.8ﾱ129.0 s and
91.7ﾱ118.8 s for IVA 7.5 and 10 mg
bid, respectively vs 78.8ﾱ133.4 s for
ATE (P<0.001 for noninferiority) at
trough of drug activity after 16 wk
Noninferiority also shown after 4 wk,
with P<0.001
At peak of drug activity,
noninferiority shown after 4 wk and
16 wk for IVA vs ATE







IVA 7.5 or 10 mg bid vs
AML 10 mg od for
3 months
TAO increased by 64.7ﾱ104.9 s, 59.7
ﾱ110.8 s, and 66.6ﾱ99.1 s for IVA
7.5 mg bid, 10 mg bid, and AML 10 mg
od, respectively (P<0.001 for
noninferiority) at trough of drug activity
Increase of 27.6ﾱ91.7 s, 21.7ﾱ94.5 s,
and 31.2ﾱ92.0 s for IVA 7.5 mg bid,
10 mg bid, and AML 10 mg od,
respectively (P<0.001 for non-
inferiority) at trough of drug activity
AML, amlopidine; ATE, atenolol; bid, twice a day; CAD, coronary artery disease; IVA, ivabradine; od, once daily; PLA, placebo; RCT, randomized controlled trial; SAP, stable angina pectoris;
TAO, time to angina onset; TLA, time to limiting angina; wk, week.
Table 3 | Antianginal effects of ivabradine in pateints with SAP7
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Antiischemic effects (Table 5)
Time to 1 mm ST segment depression during exercise (Table 5)
An increase in the TST during exercise tolerance test at trough
drug activity was observed in patients treated with ivabradine
over a period of 2 weeks in a placebo-controlled trial (Borer et
al. 2003). This was the primary efficacy endpoint of that study.
The improvement was dose-dependent, being 32.0ﾱ74.3 s,
44.1ﾱ80.1 s, and 46.2ﾱ78.2 s for ivabradine 2.5 mg twice daily,
5 mg twice daily, and 10 mg twice daily, respectively, at trough
drug activity. The difference versus placebo was significant
both for the ivabradine 5 mg twice daily and 10 mg twice daily
groups. Benefits were also observed when the exercise
tolerance test was performed at peak drug activity. During the
randomized withdrawal phase, the ivabradine groups also had
significantly higher TST than placebo.
In the INITIATIVE study (Tardif et al. 2005), the noninferiority of
ivabradine at dosages of 7.5 mg twice daily and 10 mg twice
daily was demonstrated versus atenolol 100 mg once daily at
trough drug activity for TST during treadmill exercise tolerance
test after 16 weeks. After the first 4 weeks of treatment, the
efficacy of ivabradine at trough versus atenolol was also
observed, the increase in TST being 68.8ﾱ122.5 s for
ivabradine 5 mg twice daily and 67.2ﾱ132.3 s for atenolol
50 mg once daily (P<0.001 for noninferiority). TST was
evaluated in a subpopulation of the INITIATIVE trial composed
of patients aged ≥65 years (Tendera et al. 2006), and the
efficacy of ivabradine 7.5 mg twice daily was maintained
compared with the overall population of the trial.
In the double-blind trial comparing ivabradine 7.5 mg twice
daily and 10 mg twice daily with amlodipine 10 mg once daily,
the efficacy of ivabradine for TST during exercise was
demonstrated (P<0.001 for noninferiority) after a 3-month
treatment period (Ruzyllo et al. 2007). The increases in TST
were 44.9ﾱ98.6 s, 34.7ﾱ104.5 s, and 39.7ﾱ103.2 s, respectively,
in the three study groups.
Decrease of heart rate and rate-pressure product
The HR at rest and at peak exercise in an exercise tolerance test
were both significantly decreased relative to placebo (P<0.05) in the
patients who were randomly assigned to one of the three ivabradine
groups (2.5, 5, or 10 mg twice daily) for 2 weeks in a placebo-
controlled double-blind trial (Borer et al. 2003). The reduction was
dose-dependent and was observed at both peak and trough
drug activity. During the randomized withdrawal phase, the mean
resting HR of patients remaining on ivabradine 10 mg twice daily
decreased by 0.44ﾱ5.6 bpm, compared with a mean increase of
13.3ﾱ8.8 bpm in patients switching to placebo (P<0.001).
In the same trial, the rate-pressure product (RPP) at peak exercise
decreased in the three ivabradine groups at trough drug activity,
Level of
evidence
Reference Design and patients Treatment regimen Outcomes




2 Borer et al.
2003
RCT (superiority trial),




IVA 2.5–10 mg bid vs PLA for
2 wk; then open-label phase
with IVA 10 mg bid for all
patients for 3 months; then IVA
10 mg bid vs PLA for 1 wk
Nonsignificant reduction with IVA
at all doses during first phase
Decrease from 4.14ﾱ5.59 at
baseline to 0.95ﾱ2.24 at the end
of the open-label phase
(P<0.001 vs baseline)
Increase by 0.74ﾱ1.95 in
patients withdrawn to PLA
(P=0.067)
Nonsignificant reduction with IVA
at all doses during first phase
Decrease from 2.28ﾱ3.74 at
baseline to 0.50ﾱ1.14 at the end
of the open-label phase (P<0.001
versus baseline)
2 Tardif et al.
2005
RCT (noninferiority trial),
939 patients with SAP
and CAD
IVA 5 mg bid vs ATE 50 mg od
for 4 wk; then IVA 7.5 mg bid or
10 mg bid vs ATE 100 mg od
for 12 wk
After 16 wk, decrease by
2.2ﾱ4.3, 2.3ﾱ4.2, and 2.7ﾱ12.3
attacks per week for IVA 7.5 mg
bid, IVA 10 mg bid, and ATE 100
mg od, respectively
After 16 wk, decrease by 1.6ﾱ4.1,
1.4ﾱ4.7, and 1.2ﾱ3.4 for IVA 7.5
mg bid, IVA 10 mg bid, and ATE
100 mg od, respectively
2 Ruzyllo et al.
2007
RCT (noninferiority trial)
including 1195 patients with
chronic stable angina and
documented CAD
IVA 7.5 or 10 mg bid vs AML
10 mg od for 3 months
Decrease of 3.0ﾱ5.0 for IVA
7.5 mg bid and 3.2ﾱ6.3 for IVA
10 mg bid vs 3.0ﾱ6.0 for AML
10 mg od (P<0.001 vs baseline
for the three arms)
No significant difference
between IVA and AML
Decrease of 1.9ﾱ4.5 for IVA
7.5 mg bid and 2.7ﾱ6.3 for IVA 10
mg bid vs 2.7ﾱ6.3 for AML
10 mg od (P<0.001 vs baseline
for the three arms)
No significant difference between
IVA and AML
AML, amlopidine; ATE, atenolol; bid, twice a day; CAD, coronary artery disease; IVA, ivabradine; od, once daily; PLA, placebo; RCT, randomized controlled trial; SAP, stable angina pectoris;
U/wk, units per week; wk, week.
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being significant for the 5 mg twice daily (–1142ﾱ3354 bpm/mm Hg)
and 10 mg twice daily (–1543ﾱ3526 bpm/mm Hg) groups
compared with the placebo group (+266ﾱ3074 bpm/mm Hg). At
peak drug activity, RPP at rest and at peak exercise were
significantly lower for the three ivabradine groups compared with
placebo (P<0.001). During the randomized withdrawal phase,
RPP at trough drug activity increased significantly for patients
assigned to placebo, both at rest and during exercise (P<0.001).
In the INITIATIVE trial, comparing ivabradine with atenolol (Tardif
et al. 2005), HR and RPP at trough drug activity were reduced in
all groups both at rest and during exercise after 4 and 16 weeks.
HR at rest was reduced by 14.3ﾱ11.9, 14.3ﾱ13.3, and
15.6ﾱ12.0 bpm at 16 weeks in the ivabradine 7.5 mg twice
daily, ivabradine 10 mg twice daily, and atenolol 100 mg once
daily groups, respectively, and by 10.3ﾱ11.1 and 12.8ﾱ11.4 bpm
at 4 weeks in the ivabradine 5 mg twice daily and atenolol
50 mg once daily groups. At peak exercise, HR was reduced by
8.6ﾱ13.7, 10.3ﾱ14.1, and 14.0ﾱ14.4 bpm at 16 weeks in the
ivabradine 7.5 mg twice daily, ivabradine 10 mg twice daily, and
atenolol 100 mg once daily groups, respectively, and by
7.5ﾱ12.7 and 11.1ﾱ12.8 bpm at 4 weeks in the ivabradine 5 mg
twice daily and atenolol 50 mg once daily groups. Overall
ivabradine induced a similar improvement in exercise capacity
than atenolol for a comparatively smaller reduction in RPP
and HR.
Both HR and RPP were significantly decreased (P<0.001 versus
baseline) in the ivabradine groups at rest and at peak exercise
in the trial comparing ivabradine with amlodipine (Ruzyllo et al.
2007). The maximal reductions in HR and in RPP were reached
after 1 month, and remained stable for the following 2 months.
As expected, the decrease in HR was minimal and not
significant with amlodipine, while the decrease in RPP was
significant but still significantly lower than for the ivabradine
groups (P<0.001).
Safety
Visual symptoms and sinus bradycardia are the main adverse
reactions observed with the use of ivabradine (Borer et al. 2003;
Tardif et al. 2005; Ruzyllo et al. 2007). The visual symptoms are
mainly phosphenes, which are episodes of enhanced brightness
in limited areas of the visual field frequently triggered by abrupt
changes in light intensity. They include photopsia, stroboscopic
effect, and nontypical blurred vision, among others. However, the
symptoms are generally transient, mild, and do not affect daily
living activities. The visual symptoms are probably caused by the
interaction of ivabradine with retinal hyperpolarization-activated
h channels, responsible for responses to bright light stimuli,
which are similar to the f ion channel located in the sinoatrial
node (Demontis et al. 2002; Savelieva & Camm 2006).
In the INITIATIVE trial, visual symptoms were reported by 16.3%
of patients receiving ivabradine 7.5 mg twice daily and 5.6% of
those in the atenolol 100 mg once daily group (Tardif et al. 2005).
Similarly, in another study, visual symptoms were reported by
13.0% of patients in the ivabradine 7.5 mg twice daily group
compared with 4.5% of patients receiving amlodipine 10 mg once
daily (Ruzyllo et al. 2007). The visual symptoms resolved
spontaneously during or after drug discontinuation, and led to
withdrawal in ≤1% of patients, compared with 1.5% of patients
Level of
evidence
Reference Design and patients Treatment regimen TST
2 Borer et al.
2003
RCT (superiority trial),




IVA 2.5–10 mg bid vs PLA for
2 wk; then open-label phase with
IVA 10 mg bid for all patients for
3 months; then IVA 10 mg bid vs
PLA for 1 wk
TST after the first phase of the trial increased by 32.0ﾱ74.3,
44.1ﾱ80.1, and 46.2ﾱ78.2 s for IVA 2.5, 5, and 10 mg bid,
respectively vs 9.0ﾱ63.6 s for PLA at trough of drug activity.
Significance was reached for IVA 5 mg bid and 10 mg bid vs
PLA (P<0.05)
At peak of drug activity, the results were larger and significance was
reached for IVA 5 mg bid and 10 mg bid vs PLA (P<0.05)
During the third phase, TST increased by 4.25ﾱ59.7 s for IVA vs
decrease of 32.0ﾱ73.7 s for PLA (P=0.003)
2 Tardif et al.
2005
RCT (noninferiority trial),
939 patients with SAP
and CAD
IVA 5 mg bid vs ATE 50 mg od for
4 wk; then IVA 7.5 mg bid or
10 mg bid vs ATE 100 mg od for
12 wk
After 16 wk, TST was increased by 98.0ﾱ153.7 (P<0.001 for
noninferiority) and 86.9ﾱ128.2 s (P=0.002 for noninferiority) for IVA
7.5 and 10 mg bid, respectively vs 95.6ﾱ147.5 s for ATE at trough
of drug activity
After 4 wk, TST was increased by 68.8ﾱ122.5 s for IVA 5 mg bid
vs 67.2ﾱ132.3 s for ATE 50 mg od at trough of drug activity
(P<0.001 for noninferiority). At peak of drug activity, noninferiority
of IVA vs ATE was shown




with chronic stable angina
and documented CAD
IVA 7.5 or 10 mg bid vs AML
10 mg od for 3 months
TST depression after exercise increased by 44.9ﾱ98.6 and
34.7ﾱ104.5 s for IVA 7.5 and 10 mg bid, respectively vs
39.7ﾱ103.2 s for AML at trough of drug activity (P<0.001 for
noninferiority)
AML, amlopidine; ATE, atenolol; bid, twice a day; CAD, coronary artery disease; IVA, ivabradine; od, once daily; PLA, placebo; RCT, randomized controlled trial; s, second; SAP, stable angina
pectoris; TST, time to 1 mm ST segment depression; wk, week.
Table 5 | Antiischemic effects of ivabradine in patients with SAP9
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withdrawing due to edema related to amlodipine. In a placebo-
controlled trial, visual symptoms were reported by 14.8% of
patients receiving ivabradine 10 mg twice daily during the double-
blind phase, versus 0% in the placebo group (Borer et al. 2003).
During the open-label phase, when all patients were assigned to
the ivabradine 10 mg twice daily regimen, visual symptoms were
reported by 17.9% of patients. Three patients voluntarily withdrew
from the trial because of these symptoms. However, it should be
noted that the dosage of ivabradine used in that trial (10 mg twice
daily) is not used clinically.
Sinus bradycardia has been reported by 4.6% of patients treated
with ivabradine 7.5 mg twice daily (Tardif et al. 2005; Ruzyllo
et al. 2007). Severe bradycardia (defined as an HR less
than 40 bpm) has been shown to occur in 0.1% of patients. The
QTc interval was not increased in ivabradine recipients compared
with atenolol.
The rebound phenomenon described above can occur upon
sudden withdrawal of beta blockers (Frishman 1987; Egstrup
1988), but it has not been reported with ivabradine at the dosages
used. Also, no pharmacologic tolerance to ivabradine has been
reported. Given that ivabradine does not cross the blood–brain
barrier, it has no effect on the central nervous system (Savelieva
& Camm 2006). A tolerability profile similar to that in the overall
population was observed in an elderly subpopulation with
documented CAD (Tendera et al. 2006). The large clinical
development program involving 5000 patients with SAP showed
that ivabradine has a good tolerability profile with minimal adverse
effects that have little impact on patient acceptability.
In summary, clinical evidence shows that ivabradine is a very
good antiischemic agent, being at least as effective as beta
blockade and CCA therapy in controlling anginal symptoms,
with an acceptable tolerability and safety profile.
Economic evidence and resource utilization
To our knowledge, a cost-effectiveness study has yet to be
conducted to evaluate the economic impact of ivabradine in
patients with SAP. In the US, the direct and indirect costs of
CAD have been estimated to be $US156.4 billion in 2008
(AHA 2008). In 2005, 469 000 coronary artery bypass graft
(CABG) procedures and 1 265 000 percutaneous coronary
interventions (PCI) were performed (AHA 2008). Treatment with
ivabradine could decrease the need for invasive
revascularization and its associated cost. In a study including
883 women with CAD, the estimated lifetime cost of drug
treatment and hospitalization was $US767 288 for non-
obstructive CAD and $US1051 302 for two-vessel CAD, with
25.5–32.6% of these costs attributable to drugs (Shaw et al.
2006). Thus, drug therapy accounts for a significant cost
component in patients with CAD.
It has, however, been shown that PCI is likely to be less cost
effective than drug therapy in terms of quality-adjusted life-
years when this was assessed in a prospective observational
study involving 1720 patients (Griffin et al. 2007). Similarly, a
post-hoc cost-effectiveness analysis conducted in Italy
comparing standard treatment for CAD versus standard
treatment plus amlodipine showed that savings were achieved
with antianginal therapy because of a reduction in the need for
revascularization (De Portu et al. 2006). As a consequence,
ivabradine may play a role in the future by reducing the need for
PCI in SAP patients, improving cost effectiveness of the
treatment for SAP, but further population studies must be
conducted to confirm this hypothesis.
In its more recent Guidelines for the Management of Angina Pectoris
(ESC 2006), the European Society of Cardiology (ESC) has
recommended the use of ivabradine as an alternative treatment for
SAP if beta blockers are not tolerated or are contraindicated.
Patient group/population
Ivabradine shares with beta blockers the property of decreasing
HR and oxygen demand from the ischemic heart, which is
presumably fundamentally important in mediating antiischemic
effects. In light of the positive results obtained in clinical trials, the
place of ivabradine in the therapeutic armamentarium must be
considered. Given the absence of cardiac effects other than
exclusive HR lowering, ivabradine is probably suitable for most
patients with SAP and is of particular interest in patients in whom
beta blockers should be avoided (those with AV block, peripheral
vascular disease, and obstructive pulmonary disease) and in
those in whom tolerability of beta blockers or CCAs is an issue.
Unlike beta blockers, ivabradine may be used in vasospastic
angina because it does not increase coronary vasomotor tone.
In addition to depression, fatigue, and cold extremities, erectile
dysfunction is a particularly important side effect associated with
the use of beta blockers in middle-aged men. CCAs or ivabradine
may therefore be very useful in such patients. While asthma or
chronic obstructive pulmonary disease represent only relative
contraindications to beta blockade, some patients clearly develop
bronchospasm and wheezing with beta blockers, which requires
dose reduction or abrupt withdrawal. Such patients who require
HR reduction would clearly benefit from the lack of this airways
side effect with CCAs or ivabradine. Furthermore, some patients
with both CAD and chronic obstructive pulmonary disease
develop angina when treated with inhaled beta-adrenergic
agonists because of the resulting tachycardia. The HR reduction
obtained with ivabradine could also be very helpful in this setting.
Patients with CAD can have variable degrees of AV block that
develop or are exacerbated with beta blockers. The need for
selective HR reduction in patients with myocardial ischemia and
mild AV node conduction abnormalities represents another
indication for ivabradine. This is particularly relevant for older
patients with a prolonged PR interval.
In summary, ivabradine can be used for the treatment of stable
patients with CAD and angina who are intolerant of or have
contraindications to beta blockers. It is also a logical addition for
the treatment of angina when symptoms are not controlled by
previous antianginal medications.Ivabradine | clinical impact review
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Dosage, administration, and formulations
Ivabradine was approved in the EU by the European Medicines
Agency on October 25, 2005, under the brand names Procoralan
and Corlentorﾮ (Servier) (EMEA 2007). It is also available as the
brand names Coralanﾮ and Coraxanﾮ. As a pure HR-lowering
agent, it is a unique medication from a new therapeutic class. It is
available in 5 and 7.5 mg film-coated tablets for oral
administration. Its therapeutic indication is for symptomatic
patients with chronic SAP and sinus rhythm who have a
contraindication or intolerance to beta blockers. The starting dose
should be 5 mg twice daily, which may be titrated to 7.5 mg twice
daily if the response is not enough after 3 or 4 weeks of treatment.
The drug should be taken once in the morning and once in the
evening with meals. If the HR is persistently under 50 bpm or if
patients experience bradycardic symptoms like dizziness,
hypotension, or fatigue, the dosage should be titrated downward
to 2.5 mg twice daily (half of a 5 mg tablet). A lower starting dose
should be considered for elderly patients, and ivabradine is not
recommended for children or adolescents. Ivabradine should be
used with caution if the creatinine clearance is below 15 mL/min
(0.25 mL/s) since no safety data are available for this population
of patients. It is presently contraindicated for patients with severe
hepatic insufficiency, hypersensitivity, and in the presence of
sinus bradycardia, cardiogenic shock, acute MI, severe
hypotension, sick sinus syndrome, sinoatrial block, heart failure
(New York Heart Association class III-IV), third degree AV block, a
pacemaker, and unstable angina.
Ivabradine should not be combined with strong cytochrome P450
3A4 (CYP3A4) inhibitors. Concomitant use of ivabradine with
nondihydropyridine CCAs such as verapamil or diltiazem is not
recommended, but no safety issues have been raised regarding
the combination with nitrates and dihydropyridine CCAs such as
amlodipine. Ivabradine should also not be prescribed to pregnant
and lactating women.
Stopping treatment should be considered, along with other possible
causes such as retinal disease, if unexpected deterioration of visual
function occurs, because the long-term retinal effects of ivabradine
are not known. Nevertheless, a detailed ophthalmologic study of
300 patients has not revealed any structural eye abnormalities after
12 months of treatment with ivabradine (unpublished data). Close
monitoring of patients with a prolonged QT interval is needed if the
use of ivabradine cannot be avoided.
Clinical value
HR slowing is an integral part of an optimal pharmacologic
antiischemic and antianginal strategy. Beta blockers have
traditionally been considered as a first-line therapy for stable
angina, but their use may be limited by side effects including
fatigue, depression, and sexual dysfunction. Bronchospasm and
AV block represent other limitations of beta blockers. Ivabradine
is a selective and specific If inhibitor with antianginal and
antiischemic effects that have been shown to be noninferior to
those of the beta blocker atenolol and the CCA amlodipine. Unlike
beta blockers, ivabradine is devoid of intrinsic negative inotropic
effects and does not affect coronary vasomotion. A whole range
of patients with angina may benefit from exclusive HR reduction
with ivabradine, including those with contraindications or
intolerance to the use of beta blockers and patients who are
insufficiently controlled by beta blockers or CCAs.
The efficacy of combination therapy with ivabradine and atenolol
is currently being assessed in a randomized, double-blind,
placebo-controlled trial of 750 patients with documented SAP
and CAD and previous treatment with a beta blocker. The ability
of ivabradine to decrease HR without depressing left ventricular
function also makes it a potentially very interesting medication for
the treatment of angina in patients with left ventricular
dysfunction. The ongoing BEAUTIFUL (morBidity-mortality
EvAlUaTion of the If inhibitor ivabradine in patients with coronary
disease and left ventricULar dysfunction) study is assessing the
effect of ivabradine on cardiovascular outcomes in patients with
both CAD and left ventricular systolic dysfunction, and the results
of this major clinical trial are expected in 2008 (Fox et al. 2006).
Finally, the ongoing SHIFT (Systolic Heart failure treatment with
the If inhibitor ivabradine Trial) is evaluating the potential role of
ivabradine in reducing cardiovascular mortality and morbidity in
patients with heart failure and at least moderate left ventricular
systolic dysfunction (ISRCTN 2008).
Acknowledgments
Dr Tardif has received honoraria from Servier Laboratories.
Guillaume Marquis-Gravel declares no conflict of interest.
References
AHA (American Heart Association). Heart disease and stroke statistics. 2008.
Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000090
(accessed February 2008).
Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in
combination with atenolol in stable angina. Lancet. 1991;338:1036–1039.
Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group.
Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable
angina: a randomized, double-blind, multicentered, placebo-controlled trial.
Circulation. 2003;107:817–823.
Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties
and therapeutic use in coronary artery disease. Drugs. 1996;51:792–819.
Campeau L. Letter: grading of angina pectoris. Circulation. 1976;54:522–523.
Cheitlin MD, Hutter AM Jr, Brindis R, et al. ACC/AHA expert consensus
document. Use of sildenafil (Viagra) in patients with cardiovascular disease.
American College of Cardiology/American Heart Association. J Am Coll Cardiol.
1999;34:1850.
Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility
to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol.
2003;284:H676–H682.
Coumel P. Safety of bepridil: from review of the European data. Am J Cardiol.
1992;69:75D–78D.
Cucherat M. Quantitative relationship between resting heart rate reduction and
magnitude of clinical benefits in post-myocardial infarction: a meta-regression
of randomized clinical trials. Eur Heart J. 2007;28:3012–3019.
Deckers JW. Epidemiological review of stable angina. In: Fox K, Ferrari R, editors.
Heart rate management in stable angina. Abingdon: Taylor & Francis; 2005,pp.1–16.
Demontis GC, Moroni A, Gravante B, et al. Functional characterisation and
subcellular localisation of HCN1 channels in rabbit retinal rod photoreceptors.
J Physiol. 2002;542:89–97.11
Ivabradine | clinical impact review
Core Evidence 2008;3(1)
De Portu S, Menditto E, Scalone L, Bustacchini S, Cricelli C, Mantovani LG.
The pharmacoeconomic impact of amlodipine use on coronary artery disease.
Pharmacol Res. 2006;54:158–163.
Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll
Cardiol. 1983;1:574–575.
Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of
resting heart rate in patients with suspected or proven coronary artery disease.
Eur Heart J. 2005;26:967–974.
DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If
current inhibition with ivabradine: a new therapeutic perspective in
cardiovascular disease. Drugs. 2004;64:1757–1765.
Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal
therapy in chronic stable angina. Am J Cardiol. 1988;61:1219–1222.
EMEA (European Medicines Agency). EPARs for authorised medicinal products
for human use. 2007. Available at:
http://www.emea.europa.eu/humandocs/Humans/EPAR/procoralan/procoralan.
htm (accessed August 2007).
ESC (European Society of Cardiology). The Task Force on the Management of
stable angina pectoris of the European Society of Cardiology. Guidelines on the
management of stable angina pectoris. 2006. Available at:
http://www.escardio.org/NR/rdonlyres/16E8EA50-50AA-467E-B53E-
C55E83F05D8A/0/guidelines_Angina_FT_2006.pdf (accessed July 2007).
Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The
effect of nisoldipine as compared with enalapril on cardiovascular outcomes in
patients with non-insulin-dependent diabetes and hypertension. N Engl J Med.
1998;338:645–652.
Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden
European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination
on the exercise test and the total ischaemic burden in 608 patients with stable
angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee.
Rationale and design of a randomized, double-blind, placebo-controlled trial of
ivabradine in patients with stable coronary artery disease and left ventricular
systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor
ivabradine in patients coronary disease and left ventricULar dysfunction
(BEAUTIFUL) study. Am Heart J. 2006;152:860–866.
Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol.
1987;59:26F–32F.
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality
in patients with coronary heart disease. Circulation. 1995;92:1326–1331.
Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and
short-term prognosis of angina pectoris. Br Heart J. 1995;73:193–198.
Gibbons RJ, Abrams J, Chatterjee K, et al; ACC/AHA Task Force on Stable
Angina Guidelines. ACC/AHA 2002 guidelines update for the management of
patients with chronic stable angina. Available at:
http://www.acc.org/qualityandscience/clinical/guidelines/stable/stable_clean.
pdf (accessed July 2007).
Griffin SC, Barber JA, Manca A, et al. Cost effectiveness of clinically
appropriate decisions on alternative treatments for angina pectoris: prospective
observational study. BMJ. 2007;334:624.
Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanism of beneficial effect
of beta-adrenergic blockade on exercise-induced myocardial ischemia in
conscious dogs. Circ Res. 1987;60:738–746.
Hanania G, Cambou JP, Gu￩ret P, et al; USIC 2000 Investigators. Management
and in-hospital outcome of patients with acute myocardial infarction admitted
to intensive care units at the turn of the century: results from the French
nationwide USIC 2000 registry. Heart. 2004;90:1404–1410.
Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials
comparing beta-blockers, calcium antagonists, and nitrates for stable angina.
JAMA. 1999;281:1927–1936.
Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate
are associated with coronary plaque disruption. Circulation.
2001;104:1477–1482.
ISRCTN (International Standard Randomised Controlled Trial Number). Effects
of ivabradine on cardiovascular events in patients with moderate to severe
chronic heart failure and left ventricular systolic dysfunction. A three-year
randomised double-blind placebo-controlled international multicentre study.
2008. Available at: http://www.controlled-
trials.com/ISRCTN70429960/ivabradine (accessed February 2008).
Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of
cardiovascular disease: the Framingham study. Ann Intern Med.
1976;85:447–452.
Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and
cardiovascular mortality: the Framingham Study. Am Heart J.
1987;113:1489–1494.
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-
blocker therapy and symptoms of depression, fatigue, and sexual dysfunction.
JAMA. 2002;288:351–357.
Lacoste LL, Th￩roux P, Lid￳n RM, Colucci R, Lam JY. Antithrombotic properties
of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol.
1994;73:1058–1062.
Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of
ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left
ventricular function in patients with left ventricular dysfunction. Cardiology.
2003;100:149–155.
Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-
cause, cardiovascular and cancer mortality. Eur Heart J. 1997;18:1404–1410.
Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-
based secondary prevention therapies in coronary artery disease. Circulation.
2006;113:203–212.
Pepine CJ. Angina pectoris in a contemporary population: characteristics and
therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther. 1998;12
(Suppl. 3):211–216.
Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum
heart rate and coronary atherosclerosis: independent relations to global severity
and rate of progression of angiographic lesions in men with myocardial
infarction at a young age. Am Heart J. 1992;123:609–616.
Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in
patients with stable angina pectoris: The Angina Prognosis Study in Stockholm
(APSIS). Eur Heart J. 1996;17:76–81.
Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of
ivabradine compared with amlodipine in patients with stable effort angina
pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Drugs. 2007;67:393–405.
Saha M, Marber MS. If at first you don’t succeed try…a new target in the
treatment of angina. Eur Heart J. 2005;26:2482–2483.
Savelieva I, Camm JA. Novel If current inhibitor ivabradine: safety
considerations. In: Camm J, Tendera M, editors. Heart rate slowing by If current
inhibition. Basel: Karger; 2006, pp. 79–96 (Advances in Cardiology, vol 43).
Shaw LJ, Merz CN, Pepine CJ, et al; Women's Ischemia Syndrome Evaluation
(WISE) Investigators. The economic burden of angina in women with suspected
ischemic heart disease: results from the National Institutes of Health-National
Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome
Evaluation. Circulation. 2006;114:894–904.
Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary
hemodynamic effects of S16257, a new bradycardic agent, in resting and
exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–666.
Singh BN. Safety profile of bepridil determined from clinical trials in chronic
stable angina in the United States. Am J Cardiol. 1992;69:68D–74D.
Singh BN. Morbidity and mortality in cardiovascular disorders: impact of
reduced heart rate. J Cardiovasc Pharmacol Therapeut. 2001;6:313–331.
Tafreshi MJ, Weinacher AB. Beta-adrenergic-blocking agents in bronchospastic
diseases: a therapeutic dilemma. Pharmacotherapy. 1999;19:974–978.
Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators.
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in
patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536.
Tendera M. If inhibition: from pure heart rate reduction to treatment of stable
angina. Eur Heart J Suppl. 2005;7(Suppl. H):H3–H6.Tendera M, Fox K, Tardif JC, Ford I. Anti-ischemic and antianginal efficacy of
ivabradine, a selective and specific If current inhibitor, in elderly patients with
stable angina. Circulation. 2006;114(Suppl. II):715. (Abstract)
Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin
Drug Saf. 2006;5:667–674.
Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine
gastrointestinal therapeutic system and atenolol on antianginal efficacies and
exercise hemodynamic responses in stable angina pectoris. Am J Cardiol.
1994;73:23–28.
Zaza A, Rocchetti M. Regulation of the sinoatrial pacemaker: selective If
inhibition by ivabradine. In: Fox K, Ferrari R, editors. Heart rate management in
stable angina. Abingdon: Taylor & Francis; 2005, pp. 51–67.
Correspondence: Jean-Claude Tardif, MD, Research Center,
Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec,
Canada H1T 1C8 or at jean-claude.tardif@icm-mhi.org
Ivabradine | clinical impact review
ﾩ 2008 Core Medical Publishing Limited 12